Dr Schon obtained his PhD in cancer research from The University of Cambridge and completed his postdoc research in the laboratory of Nobel Prize laureate Sir Gregory Paul Winter, FRS. He has worked in cancer research for 20 years, starting his career in 2003 as one of the initial domain antibody scientists at Winter’s company Domantis Ltd, which was acquired by GlaxoSmithKline three years later.
“I’m pleased that BiVictriX has been able to attract an executive of Oliver’s calibre which is testament to the growing interest in our Bi-Cygni therapeutics platform which aims to leverage clinical experience to develop a class of highly selective, next-generation cancer therapeutics. Oliver’s long career in cancer research, most recently leading teams in antibody-based therapeutics development and manufacturing, will be invaluable as we build our internal capabilities, progress our lead asset BVX001 and expand our pipeline,” said Tiffany Thorn, the chief executive of BiVictriX.
Dr Schon said he is joining the company at a formative time as BiVictriX prepares to progress lead optimisation of BVX001 to reach key preclinical milestones on efficacy and safety following a successful listing on London’s AIM market last month.
The emerging biotechnology company, which is applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience, added that James Griffin, a joint PhD student between University of Liverpool (UoL) and BiVictriX, has been appointed as part of a Medical Research Council (MRC)-lead doctoral training programme.
Griffin will study as an MRC Discovery Medicine North iCASE Doctoral Training Programme Postgraduate Research Student and will carry out research in an academia-industry partnership. The doctoral training scheme is fully funded by the MRC, with opportunities for Griffin to support the BiVictriX drug development objectives at UoL and on BiVixtriX’s premises.
This arrangement enables BiVictriX to expand its existing collaboration with the UoL, providing specialist access and expertise to expand the company’s use of state-of-the-art techniques, including assessing UoL’s Mass CyTOFF facility, which will be pivotal in the company’s ongoing activities to identify and validate further proprietary cancer-specific twin antigen fingerprints.
Shares in BiVictriX were up 2.6% at 20p in lunchtime trading.